Menu
Menu
Going public

Going public

FRAMINGHAM (01/15/2004) - Biotech Immunicon, a developer of cell-based research and diagnostic products for cancer, filed for an initial public offering with the SEC last month. Applying for a Nasdaq listing under the symbol "IMMC," the company stands to raise as much as US$86.2 million, although it did not specify share price or the number of shares it planned to offer in the IPO.

Join the CIO New Zealand group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.

Join the newsletter!

Error: Please check your email address.

More about SEC

Show Comments

Market Place